Mediwound (NASDAQ:MDWD) and Pharmacyte Biotech (OTCMKTS:PMCB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.
This is a summary of current ratings and price targets for Mediwound and Pharmacyte Biotech, as provided by MarketBeat.
Mediwound presently has a consensus target price of $12.50, suggesting a potential upside of 188.68%. Given Mediwound’s higher possible upside, equities analysts plainly believe Mediwound is more favorable than Pharmacyte Biotech.
Institutional & Insider Ownership
31.9% of Mediwound shares are held by institutional investors. Comparatively, 0.1% of Pharmacyte Biotech shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Mediwound and Pharmacyte Biotech’s net margins, return on equity and return on assets.
Earnings & Valuation
This table compares Mediwound and Pharmacyte Biotech’s revenue, earnings per share and valuation.
Pharmacyte Biotech has lower revenue, but higher earnings than Mediwound.
Volatility and Risk
Mediwound has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Pharmacyte Biotech has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500.
Mediwound beats Pharmacyte Biotech on 5 of the 9 factors compared between the two stocks.
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
About Pharmacyte Biotech
PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the Cannabis plant. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.